Adobe Inc. filed a Form 8-K with the SEC on September 10, 2026, disclosing that it issued a press release announcing financial results for its third quarter of fiscal year 2026, which ended August 28, 2026.
AptarGroup, Inc. filed a Form 8-K on September 10, 2026, disclosing the resignation of its Vice President and Chief Accounting Officer and the appointment of an interim replacement effective September 11, 2026.
Carlisle Companies Incorporated filed an 8-K with the U.S. Securities and Exchange Commission on September 10, 2026, disclosing the resignation of director Jesse G. Singh and a reduction in board size to six members.
Adamas Trust, Inc. filed a Form 8-K on September 10, 2026, announcing that its Board of Directors declared cash dividends on four series of cumulative redeemable preferred stock for the dividend period beginning July 15, 2026 and ending October 14, 2026.
A Statement of Changes in Beneficial Ownership filed on September 10, 2026 discloses that Sascha Zahnd, a director of Logitech International S.A. (NASDAQ:LOGI), acquired 2,518 restricted stock units at no cost on September 8, 2026.
A Statement of Changes in Beneficial Ownership was filed on September 10, 2026, reporting that Logitech International S.A. director Deborah Thomas acquired 2,518 restricted stock units on September 8, 2026, at a price of $0 per unit.
Autodesk, Inc. filed a Form 8-K on September 10, 2026, disclosing the entry into an underwriting agreement and the issuance of $1 billion in senior notes across two tranches, with proceeds intended to repay an existing term loan credit facility.
Logitech International S.A. filed a Form 8-K on September 10, 2026, reporting the results of its Annual General Meeting held on September 8, 2026, including votes on board elections, compensation, dividends, and Articles of Incorporation amendments, and announcing related dividend dates.
Organogenesis is a regenerative-medicine company focused on advanced wound care and surgical and sports medicine, with a portfolio that has long included skin-substitute and tissue products such as Apligraf and Dermagraft. In the second quarter of 2026, the company reported revenue of $42.8 million, …
BeyondSpring is a clinical-stage biopharmaceutical company developing plinabulin, a selective immunomodulating microtubule-binding agent, for cancer treatment. In 2026 the company reported notable clinical signals: Phase 2 data presented at ASCO showed a 58% two-year overall survival rate in metastatic non-small cell lung cancer patients …